Evogene (EVGN) Cash & Equivalents (2012 - 2026)

Evogene has reported Cash & Equivalents for 15 years, with the latest figure at $8511.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 99.89% year-over-year to $8511.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8511.0 (down 99.89% YoY) and the FY2025 annual result came in at $13.0 million, down 15.33% from the prior year.
• Cash & Equivalents fell to $8511.0 in Q1 2026 per EVGN's latest filing, from $13.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $36.0 million in Q1 2022 and troughed at $8511.0 in Q1 2026.
• A 5-year average of $17.6 million and a median of $15.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents fell 6.8% in 2022, then slumped 99.89% in 2026.
• Over 5 years, Cash & Equivalents stood at $29.0 million in 2022, then declined by 28.32% to $20.8 million in 2023, then fell by 26.34% to $15.3 million in 2024, then declined by 15.33% to $13.0 million in 2025, then tumbled by 99.93% to $8511.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $8511.0, $13.0 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.